Alira Health

ESMO Congress 2024

September 13-17, 2024 | Barcelona, Spain

We are excited to share that we will join the ESMO Congress, a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

At Alira Health, we advise companies with our extensive and cross-functional expertise, including market access, pricing, real-world evidence, and transaction advisory. Take this opportunity to connect with our delegates and discover how we can help you accelerate innovation and deliver tomorrow’s standard of care for oncology patients.

Want to connect at ESMO? Contact us to set up a meeting. 

Meet Our Delegates

Fred Calado

Frederico Calado
Vice President,
Global Real-World Solutions 

Mathieu Rose

Mathieu Rosé
Director,
Global Real-World Solutions

Catia Proenca

Catia Proenca
Director,
Global Real-World Solutions

Ahmad Bechara

Ahmad Bechara
Executive Vice President,
Global Pharma

Isabel De La Paz
Engagement Manager,
Market Access and Pricing

Benedetta Zaniboni
Consultant,
Market Access and Pricing

Aaron Grandy
Principal,
Market Access and Pricing

Giuseppe Gulotta
Principal,
Market Access and Pricing

giovanni selvaggi

Giovanni Selvaggi
Senior Vice President,
Medical Strategy

Bob Delise
Managing Partner,
Artisan Healthcare Consulting,
an Alira Health Company

Discover Our Latest Nuclear Medicine Case Studies

A mid-sized pharma was conducting a Phase III trial designed to support registration and launch of a radiopharmaceutical therapy in the US and sought support to rapidly assess and identify gaps in their evidence generation strategy and develop a mitigation plan.

Learn more    

A US biopharma needed to validate the patient journeys and US reimbursement pathways for their two alpha-emitting radioligand therapies in two solid tumor indications. They also sought to understand the suitable price points for each asset.

Learn more

A European biotech specializing in the development of radioligand therapies (RLTs) sought to assess the sales potential of its drug candidate, considering the current and future market landscape, especially the positioning of prostate-specific membrane antigen-targeting RLTs.

Learn more 

Discover How We Support Our Clients

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.